News stories about Zoetis (NYSE:ZTS) have trended somewhat positive on Thursday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zoetis earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.8196789630085 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
Zoetis (NYSE:ZTS) opened at $76.73 on Thursday. The firm has a market capitalization of $38,179.04, a P/E ratio of 35.94, a price-to-earnings-growth ratio of 1.73 and a beta of 1.06. Zoetis has a 1 year low of $52.00 and a 1 year high of $80.13. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.52 EPS. sell-side analysts forecast that Zoetis will post 2.36 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be issued a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, January 18th. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.66%. Zoetis’s payout ratio is presently 26.32%.
Several equities analysts have recently weighed in on ZTS shares. BMO Capital Markets reiterated a “hold” rating and set a $65.00 price objective on shares of Zoetis in a report on Thursday, November 2nd. Cowen set a $80.00 price objective on Zoetis and gave the company a “buy” rating in a report on Friday, November 17th. Morgan Stanley upgraded Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price objective on the stock in a report on Wednesday, November 29th. UBS Group reiterated a “neutral” rating on shares of Zoetis in a report on Friday, November 24th. Finally, Citigroup upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company’s stock. Zoetis has an average rating of “Buy” and an average target price of $73.72.
ILLEGAL ACTIVITY NOTICE: “Zoetis (NYSE:ZTS) Given Coverage Optimism Score of 0.20” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/01/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-zoetis-zts-stock-price.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.